Home Tools
Log in
Cart

Search Result

Search Results for " cdks "

20

Compounds

Cat No. Product Name Synonyms Targets
T17143 Toyocamycin Vengicide Apoptosis , Others , IRE1 , Antibiotic , Antifungal
Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM). Toyocamycin induces apoptosis.
T8819 SU-9516 CDK
SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
T7698 BS194 CDK
BS194 is as a potent cyclin-dependent protein kinases (CDKs) inhibitor.
T5533 MC180295 (rel)-MC180295 CDK
MC180295 ((rel)-MC180295) is a novel potent, highly selective CDK9 inhibitor (IC50: 5 nM), displays >22-fold selectivity over other CDKs.
T5200 Indirubin-3'-monoxime Indirubin-3'-oxime GSK-3 , Lipoxygenase , CDK
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin E).
T6837 Flavopiridol L868275,Alvocidib,NSC 649890 HCl,HMR-1275 Apoptosis , HIV Protease , CDK , Autophagy
Flavopiridol (Alvocidib) (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially foun...
T6177 PF-562271 besylate PF-00562271 Besylate FAK , PYK2 , CDK
PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, exc...
T21768 PF-562271 hydrochloride PF-562271 HCl FAK , PYK2 , CDK
PF-562271 hydrochloride (PF-562271 HCl) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other pr...
T2615 Flavopiridol hydrochloride Alvocidib Hydrochloride,NSC 649890,MDL 107826A,HL 275,FLAVOPIRIDOL HCL,NSC 649890 HCl HIV Protease , CDK , Autophagy
Flavopiridol hydrochloride (MDL 107826A) is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of ...
T16359 NU6140 CDK , Aurora Kinase
NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also e...
T10745 CDK9-IN-7 CDK
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
T6458 CYC-116 VEGFR , FLT , CDK , S6 Kinase , Aurora Kinase
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 ...
T23093 NSC 693868 Others
CDKs and GSK-3 inhibitor
T71121 Milciclib maleate
Milciclib maleate is an inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA).
T2653 SB1317 TG02 FLT , JAK , CDK
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
T16784 Roniciclib BAY 1000394 CDK
Roniciclib (BAY 1000394) is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) v...
T28532 RGB-286147
RGB-286147 is a potent, selective, ATP-competitive Cdks inhibitor.
T70707 Paullone
Paullone is an inhibitor of cyclin-dependent kinases (CDKs). The CDKs are a family of protein kinases that are involved in regulation of the cell cycle.
T41019 Histone H1-derived Peptide Histone H1-derived Peptide
Histone H1-derived peptide is a phosphopeptide with peptide substrates that consist of a sequence aligned with the optimal recognition motif for cyclin-dependent kinases (CDKs).
T62943 ZLWT-37
ZLWT-37 is a potent, orally active inhibitor of CDKs, acting on CDK9 (IC50: 0.002 μM) and CDK2 (IC50: 0.054 μM). ZLWT-37 is capable of blocking the cell cycle of HCT116 cells in G2/M phase and apoptosis.
1 2
TargetMol